Cargando…

Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity

RATIONALE: It is well known that diabetes mellitus (DM) exacerbates the mechanisms underlying atherosclerosis. Currently, glucagon-like peptide-1 receptor agonists (aGLP-1) have one of the most prominent cardioprotective effects among the antidiabetic agents. However, the treatment with aGLP-1 is ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Babenko, Alina Yu., Savitskaya, Daria A., Kononova, Yulia A., Trofimova, Aleksandra Yu., Simanenkova, Anna V., Vasilyeva, Elena Yu., Shlyakhto, Evgeny V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421820/ https://www.ncbi.nlm.nih.gov/pubmed/30944827 http://dx.doi.org/10.1155/2019/1365162

Ejemplares similares

Tissue and Circulating MicroRNAs 378 and 142 as Biomarkers of Obesity and Its Treatment Response
por: Matveev, Georgy A., et al.
Publicado: (2023)

Predictors of Carbohydrate Metabolism Disorders and Lethal Outcome in Patients after Myocardial Infarction: A Place of Glucose Level
por: Kononova, Yulia, et al.
Publicado: (2023)

Metformin: Expanding the Scope of Application—Starting Earlier than Yesterday, Canceling Later
por: Kononova, Yulia A., et al.
Publicado: (2022)

Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis
por: Lebedev, D. A., et al.
Publicado: (2020)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population
por: Zhebrun, Daria, et al.
Publicado: (2011)

The Atrial Fibrillation Risk Score for Hyperthyroidism Patients
por: Derevitskii, Ilya V., et al.
Publicado: (2020)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Low 25(OH)D Level Is Associated with Severe Course and Poor Prognosis in COVID-19
por: Karonova, Tatiana L., et al.
Publicado: (2021)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
por: Alorfi, Nasser M, et al.
Publicado: (2022)

A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
por: Griffith, David A., et al.
Publicado: (2022)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
por: Ren, Qingjuan, et al.
Publicado: (2022)

Is there a role for glucagon‐like peptide‐1 receptor agonists in the treatment of male infertility?
por: Cannarella, Rossella, et al.
Publicado: (2021)

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
por: Sawami, Kosuke, et al.
Publicado: (2022)

Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
por: Hropot, Tim, et al.
Publicado: (2023)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

The Effect of Glucagon-Like Peptide-2 Receptor Agonists on Colonic Anastomotic Wound Healing
por: Redstone, Heather A., et al.
Publicado: (2010)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus
por: Zykov, Vladislav A, et al.
Publicado: (2018)

Weight loss with glucagon‐like peptide‐1 receptor agonists in Bardet‐Biedl syndrome
por: Ganawa, Shawg, et al.
Publicado: (2022)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
por: Madsbad, Sten
Publicado: (2015)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
por: Choe, Hun Jee, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
por: Baggio, Laurie L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3p0i1u8fm7t5rqva8ggo28ivr4